NCT00527826 - Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV | Biotech Hunter

Enrollment

214

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Salmeterol / Fluticasone (50/500 µg) BID fixed combination

comparator

DRUG

Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers

comparator

Trial Locations (23)

10365

GSK Investigational Site, Berlin

13187

GSK Investigational Site, Berlin

14469

GSK Investigational Site, Potsdam

16816

GSK Investigational Site, Neuruppin

22299

GSK Investigational Site, Hamburg

30169

GSK Investigational Site, Hanover

33330

GSK Investigational Site, Gütersloh

34121

GSK Investigational Site, Kassel

35037

GSK Investigational Site, Marburg

37269

GSK Investigational Site, Eschwege

44787

GSK Investigational Site, Bochum

63571

GSK Investigational Site, Gelnhausen

65183

GSK Investigational Site, Wiesbaden

66111

GSK Investigational Site, Saarbrücken

68161

GSK Investigational Site, Mannheim

69117

GSK Investigational Site, Heidelberg

69168

GSK Investigational Site, Wiesloch

76646

GSK Investigational Site, Bruchsal

03050

GSK Investigational Site, Cottbus

09456

GSK Investigational Site, Annaberg

04275

GSK Investigational Site, Leipzig

01445

GSK Investigational Site, Radebeul

04626

GSK Investigational Site, Schmölln